# A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging

> **NCT00633022** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 99 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** LOSMAPIMOD 7.5 MG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00633022
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06-02
- **Primary completion:** 2009-12-03
- **Final completion:** 2009-12-03
- **Target enrollment:** 99 (ACTUAL)
- **Last updated:** 2018-10-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00633022

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00633022, "A Study to Evaluate the Effects of 3 Months Dosing With GW856553, as Assessed FDG-PET/CT Imaging". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00633022. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*